BioNano Genomics, Inc. WT EXP 082123 (NASDAQ:BNGOW – Get Rating) and NeoGenomics (NASDAQ:NEO – Get Rating) are both professional, scientific, and technical services companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, earnings, institutional ownership, profitability and dividends.
Valuation and Earnings
This table compares BioNano Genomics, Inc. WT EXP 082123 and NeoGenomics’ revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|BioNano Genomics, Inc. WT EXP 082123||N/A||N/A||N/A||N/A||N/A|
|NeoGenomics||$484.33 million||2.86||-$8.35 million||($1.32)||-8.30|
BioNano Genomics, Inc. WT EXP 082123 has higher earnings, but lower revenue than NeoGenomics.
|Net Margins||Return on Equity||Return on Assets|
|BioNano Genomics, Inc. WT EXP 082123||N/A||N/A||N/A|
Insider and Institutional Ownership
88.2% of NeoGenomics shares are held by institutional investors. 1.0% of NeoGenomics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
This is a breakdown of recent ratings and target prices for BioNano Genomics, Inc. WT EXP 082123 and NeoGenomics, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|BioNano Genomics, Inc. WT EXP 082123||0||0||0||0||N/A|
NeoGenomics has a consensus target price of $19.00, suggesting a potential upside of 73.52%. Given NeoGenomics’ higher probable upside, analysts clearly believe NeoGenomics is more favorable than BioNano Genomics, Inc. WT EXP 082123.
NeoGenomics beats BioNano Genomics, Inc. WT EXP 082123 on 5 of the 8 factors compared between the two stocks.
NeoGenomics, Inc. is a clinical laboratory company, which engages in cancer genetics diagnostic testing and pharma services. It operates through the Clinical Services and Pharma Services segments. The Clinical Services segment offers cancer testing services to community-based pathologists, hospitals, academic centers, and oncology groups. The Pharma Services segment focuses on supporting pharmaceutical firms in drug development programs by supporting various clinical trials and research. It also provides testing services in support of its pharmaceutical clients’ oncology programs from discovery to commercialization. The company was founded by Michael T. Dent on October 29, 1998 and is headquartered in Fort Myers, FL.
Receive News & Ratings for BioNano Genomics Inc. WT EXP 082123 Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNano Genomics Inc. WT EXP 082123 and related companies with MarketBeat.com's FREE daily email newsletter.